Strategic communication can mean either communicating a concept, a process, or data that satisfies a long term strategic goal of an organization by allowing facilitation of advanced planning, or communicating over long distances usually using international telecommunications or dedicated global network assets to coordinate actions and activities of operationally significant commercial, non-commercial and military business or combat and logistic subunits. It can also mean the related function within an organization, which handles internal and external communication processes. Strategic communication can also be used for political warfare. Wikipedia.


Time filter

Source Type

News Article | April 17, 2017
Site: co.newswire.com

120 West Strategic Communications of Reno, Nevada announced today that Jeff Pritchard, a veteran mining and resource investor relations (IR) professional will be joining the agency to support and cultivate 120 West mining IR clients. ​Pritchard was formerly the IR consultant with Argonaut Gold (TSX: AR) and previously was a founding executive with Capital Gold Corporation (TSX: CGC) overseeing all IR and communications. “We are very excited to have Jeff join our agency,” said 120 West President and Chief Marketing Officer Ira M. Gostin. “His experience in precious metals investor relations is extremely powerful and adds great depth to our team.” ​Pritchard is a graduate of the State University of New York and has an extensive background in marketing and communications, having worked with two National Hockey League teams early in his career. He resides in Austin, Texas. 120 West is a unique provider of comprehensive communications campaigns aligned directly toward business goals. Working with both public and private companies, 120 West employs strategic engagement to drive momentum and deliver measurable communications results. Founded in 2016 by Gostin, 120 West has created an exclusive approach to investor relations, marketing and corporate communications.


News Article | April 25, 2017
Site: globenewswire.com

Gosselies, Belgique, le 25 avril 2017, 7h CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans les domaines de l'orthopédie et des maladies osseuses, annonce aujourd'hui la publication de son Rapport annuel 2016. Bone Therapeutics est une société leader dans la thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans le domaine de l'orthopédie et des pathologies osseuses. Basée à Gosselies, Belgique, la Société dispose d'un vaste portefeuille diversifié de produits de thérapie cellulaire osseuse, en développement clinique dans divers domaines thérapeutiques ciblant des marchés caractérisés par d'importants besoins médicaux non satisfaits et des innovations limitées. Les produits de thérapie cellulaire de Bone Therapeutics sont fabriqués selon les normes des BPF les plus strictes, et protégés par un vaste portefeuille PI couvrant 9 familles de brevets. De plus amples informations sont disponibles sur notre site www.bonetherapeutics.com/fr. Certaines déclarations, croyances ou opinions du communiqué de presse sont des déclarations prospectives, et reflètent les attentes actuelles et les projections futures relatives à des événements futurs de la Société ou, le cas échéant, de ses administrateurs. De par leur nature, les déclarations prospectives impliquent un certain nombre de risques, d'incertitudes et de suppositions qui pourraient entraîner des résultats ou événements effectifs substantiellement différents de ceux exprimés de manière explicite ou implicite dans les déclarations prospectives. Ces risques, incertitudes et suppositions peuvent affecter de manière négative les résultats et effets financiers des plans et événements décrits dans le communiqué. Une multitude de facteurs, notamment, sans s'y limiter, des modifications intervenant en matière de demande, de concurrence et de technologie, peuvent avoir pour conséquence que les événements, performances ou résultats diffèrent de manière importante des développements anticipés. Les déclarations prospectives contenues dans ce communiqué de presse qui se basent sur des tendances ou des activités passées ne constituent pas des garanties que ces tendances ou activités se poursuivront à l'avenir. En conséquence, la Société rejette expressément toute obligation ou engagement de publier des mises à jour ou révisions des déclarations prospectives de ce communiqué de presse suite à une modification des prévisions ou à une modification des événements, des conditions, des suppositions ou des circonstances sur lesquelles ces déclarations prospectives sont basées. Ni la Société ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun cadre ou employé de ces personnes ne garantit que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs et aucun de ceux-ci n'accepte la moindre responsabilité en ce qui concerne l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou la survenance effective des événements prévus. Il ne faut pas placer une confiance indue dans les déclarations prospectives, qui ne concernent que la situation telle qu'elle se présente à la date de ce communiqué de presse. Bone Therapeutics SA Thomas Lienard, Chief Executive Officer Wim Goemaere, Chief Financial Officer Tél: +32 (0)2 529 59 90 investorrelations@bonetherapeutics.com ou Pour les médias belges et internationaux: Consilium Strategic Communications Amber Fennell, Jessica Hodgson et Hendrik Thys Tél: +44 (0) 20 3709 5701 bonetherapeutics@consilium-comms.com ou Pour les médias et investisseurs français: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier et Nicolas Merigeau Tél: + 33 (0)1 44 71 94 94 bone@newcap.eu


Gosselies, Belgique, le 26 avril 2017, 7h CEST - BONE THERAPEUTICS (code Euronext Bruxelles et Paris : BOTHE), société de thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans les domaines de l'orthopédie et des maladies osseuses, informe ses actionnaires que son assemblée générale se tiendra le jeudi 26 mai 2017 à 16h dans les locaux de la Société, 37 Rue Auguste Piccard, 6041 Gosselies, Belgique. Les documents et renseignements préparatoires relatifs à cette assemblée sont tenus à la disposition des actionnaires et peuvent être consultés sur le site internet de la Société à l'adresse suivante : www.bonetherapeutics.com, dans la rubrique Investisseurs / Assemblée Générale, selon les dispositions légales et réglementaires applicables. Bone Therapeutics est une société leader dans la thérapie cellulaire osseuse qui répond à d'importants besoins médicaux non satisfaits dans le domaine de l'orthopédie et des pathologies osseuses. Basée à Gosselies, Belgique, la Société dispose d'un vaste portefeuille diversifié de produits de thérapie cellulaire osseuse, en développement clinique dans divers domaines thérapeutiques ciblant des marchés caractérisés par d'importants besoins médicaux non satisfaits et des innovations limitées. Les produits de thérapie cellulaire de Bone Therapeutics sont fabriqués selon les normes des BPF les plus strictes, et protégés par un vaste portefeuille PI couvrant 9 familles de brevets. De plus amples informations sont disponibles sur notre site www.bonetherapeutics.com/fr. Certaines déclarations, croyances ou opinions du communiqué de presse sont des déclarations prospectives, et reflètent les attentes actuelles et les projections futures relatives à des événements futurs de la Société ou, le cas échéant, de ses administrateurs. De par leur nature, les déclarations prospectives impliquent un certain nombre de risques, d'incertitudes et de suppositions qui pourraient entraîner des résultats ou événements effectifs substantiellement différents de ceux exprimés de manière explicite ou implicite dans les déclarations prospectives. Ces risques, incertitudes et suppositions peuvent affecter de manière négative les résultats et effets financiers des plans et événements décrits dans le communiqué. Une multitude de facteurs, notamment, sans s'y limiter, des modifications intervenant en matière de demande, de concurrence et de technologie, peuvent avoir pour conséquence que les événements, performances ou résultats diffèrent de manière importante des développements anticipés. Les déclarations prospectives contenues dans ce communiqué de presse qui se basent sur des tendances ou des activités passées ne constituent pas des garanties que ces tendances ou activités se poursuivront à l'avenir. En conséquence, la Société rejette expressément toute obligation ou engagement de publier des mises à jour ou révisions des déclarations prospectives de ce communiqué de presse suite à une modification des prévisions ou à une modification des événements, des conditions, des suppositions ou des circonstances sur lesquelles ces déclarations prospectives sont basées. Ni la Société ni ses conseillers ou représentants, ni aucune de ses filiales, ni aucun cadre ou employé de ces personnes ne garantit que les hypothèses sous-jacentes à ces déclarations prospectives sont exemptes d'erreurs et aucun de ceux-ci n'accepte la moindre responsabilité en ce qui concerne l'exactitude future des déclarations prospectives contenues dans ce communiqué de presse ou la survenance effective des événements prévus. Il ne faut pas placer une confiance indue dans les déclarations prospectives, qui ne concernent que la situation telle qu'elle se présente à la date de ce communiqué de presse. Bone Therapeutics SA Thomas Lienard, Chief Executive Officer Wim Goemaere, Chief Financial Officer Tél: +32 (0)2 529 59 90 investorrelations@bonetherapeutics.com ou Pour les médias belges et internationaux: Consilium Strategic Communications Amber Fennell, Jessica Hodgson et Hendrik Thys Tél: +44 (0) 20 3709 5701 bonetherapeutics@consilium-comms.com ou Pour les médias et investisseurs français: NewCap Investor Relations & Financial Communications Pierre Laurent, Louis-Victor Delouvrier et Nicolas Merigeau Tél: + 33 (0)1 44 71 94 94 bone@newcap.eu


PARIS, FRANCE and CHARLOTTESVILLE, VA / ACCESSWIRE / April 18, 2017 / Cellnovo Group ("Cellnovo" EN Paris: CLNV), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero's Artificial Pancreas (AP) technology into Cellnovo's mobile diabetes management system. The non-exclusive worldwide agreement allows Cellnovo to commercialize a Cellnovo-TypeZero product in the future. Integration efforts are currently underway with a product launch expected in 2018. No financial terms have been disclosed. TypeZero's AP software, known as inControl AP, will be incorporated directly into Cellnovo's Bluetooth-enabled micropump. inControl AP continuously monitors blood glucose levels via a smartphone application and automatically delivers corrections to regulate blood sugar levels through an integrated insulin pump. "Our partnership with TypeZero brings us another step closer to delivering one of the first end-to-end diabetes management systems," said Sophie Baratte, Chief Executive Officer of Cellnovo. "We are confident that this strategic collaboration will result in a sophisticated product that improves the quality of life for patients with type 1 diabetes." "The future of diabetes care is rapidly progressing toward integrated solutions that simplify the device burden that people with type 1 diabetes face," said Chad Rogers, Chief Executive Officer of TypeZero. "The Cellnovo mobile diabetes management system is an ideal platform for artificial pancreas system development because of its real-time connected data and discreetness to suit the needs and lifestyle of patients. I believe the combination of our artificial pancreas technology with Cellnovo's advanced pump system can fundamentally shift the way we treat type 1 diabetes, and we're excited about that possibility." About Cellnovo An independent medical technology company specializing in diabetes, Cellnovo has developed and markets the first mobile, connected, all-in-one diabetes management system that helps make life easier for patients. Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is currently participating in several major Artificial Pancreas projects with Diabeloop, TypeZero and Horizon 2020 to develop automated insulin delivery systems. For further information, please visit www.cellnovo.com. About the Cellnovo Diabetes Management System Compact, intuitive and entirely connected, Cellnovo's insulin pump comprises a mobile touchscreen controller with an integrated blood-glucose meter. This unique device allows optimal management of insulin injections with drop-by-drop precision, whilst ensuring extensive freedom of movement and peace of mind for patients. Thanks to the automatic transmission of data, it also allows the patient's condition to be continually monitored by family members and healthcare professionals in real time. Cellnovo is listed on Euronext, Compartment C ISIN: FR0012633360 - Ticker: CLNV About TypeZero Technologies, Inc. The world leader in clinically tested artificial pancreas solutions, TypeZero Technologies is a digital health and personalized medicine company dedicated to revolutionizing the treatment and management of diabetes. TypeZero is combining next-generation data science techniques, proven metabolic models, and modern engineering practices to develop customized analytics tools and blood glucose control solutions to help people with diabetes improve their health and lives. TypeZero's current solutions include a smartphone-based artificial pancreas system, therapy optimization tools for health care providers, and advisory applications for smart insulin pens. To learn more, visit www.typezero.com. Contact Cellnovo Chief Executive Officer Sophie Baratte investors@cellnovo.com NewCap Investor Relations Tristan Roquet Montégon + 33 1 44 71 00 16 Media Relations in France Nicolas Merigeau + 33 1 44 71 94 98 cellnovo@newcap.eu Consilium Strategic Communications Media Relations in United Kingdom Chris Gardner, Chris Welsh, Laura Thornton +44 20 3709 5700 cellnovo@consilium.com TypeZero Technologies, Inc. Meagan Collins Senior Operations Manager mcollins@typezero.com (434) 284-8919 SOURCE: Cellnovo Group ReleaseID: 459894


News Article | May 5, 2017
Site: www.prnewswire.com

"The SGDC inaugurates a new era in the history of telecommunications in Brazil, because now we can take internet via satellite to 100% of the Brazilian territory, generating social and economic benefits. We will be illuminating Brazil, with broadband internet, generating social and digital inclusion in schools, hospitals, health posts and, above all, increasing the competitiveness of Brazil," said Antonio Loss, President of Telebras. As a joint venture between Embraer and Telebras Visiona is responsible for the structuring and integration of the SGDC Program, acting among other activities in the improvement of requirements, selection and management of suppliers, validation of engineering reports, production monitoring and system tests required for mission success. For more than two years, Visiona engineers worked side by side with ThalesAlenia professionals in France in the development and production of the satellite under the technology absorption program, acquiring knowledge that will be fundamental to increase the Brazilian content of the future space programs. With an international presence and also a player in the markets for remote sensing and satellite telecommunications services, Visiona should leverage the knowledge acquired during the SGDC program to propose solutions incorporating the state-of-the-art in space construction and application technologies for the National Program Of Space Activities (PNAE) and the Strategic Program of Space Systems (PESE), always seeking the development of the Brazilian industry. ABOUT VISIONA Visiona Tecnologia Espacial S.A. is a company of the Embraer and Telebras groups, constituted with the initial objective of working on the integration of the Brazilian Government's Geostationary Defense and Strategic Communications Satellite System (SGDC), which aims to meet the Government's satellite communications needs Including the National Broadband Program (PNBL) and a broad spectrum of strategic defense communications. Visiona also aims to act as a satellite integrating company, focusing on the demands of the National Space Activities Program (PNAE / AEB) and the Strategic Space Systems Program (PESE / FAB). ABOUT TELEBRAS Telecomunicacoes Brasileiras S.A. - TELEBRAS is a publicly traded joint stock company, a strategic provider of telecommunications solutions for the Public Administration and the market, acting as agent for local development and promoting the democratization of access to information. It offers dedicated Internet access services to telecommunication service providers, which have authorization issued by Anatel; In addition to providing infrastructure to telecommunications services provided by private companies, States, Federal District, Municipalities and non-profit entities. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/visiona-announces-successful-launch-of-brazilian-geostationary-satellite-300452284.html


News Article | February 28, 2017
Site: www.businesswire.com

NEW YORK --(BUSINESS WIRE)--Falcon.io’s leading customer experience management platform has been selected by the Columbia University School of Professional Studies (SPS) to aid in boosting its social media presence while centralizing its social account management, community management, and social listening. Columbia's School of Professional Studies offers 14 master's degrees, a comprehensive portfolio of pre-professional, post baccalaureate, and lifelong learning programs, and interdisciplinary research centers. By offering market-leading degree programs across disciplines, such as Applied Analytics, Bioethics, Sports Management, Strategic Communications, Sustainability and Technology Management, the School is uniquely positioned to meet the diverse professional education needs of top recent graduates, successful mid-career professionals, and accomplished executives. “We found that the inconsistency in our social activity created a disconnect that was confusing, and potentially a turnoff, for students, alumni and faculty,” said Caroline Henley, social media specialist at Columbia University. “With the Falcon platform we have successfully centralized all of our accounts and can now cross-promote events and content, conduct social listening, and facilitate community management – all from a unified interface. Since February 2016, we have doubled the graduate school’s social following across programs and channels, launched and grown the Dean’s Twitter handle to over 5k followers.” Falcon.io’s award-winning customer experience management platform gives brands the ability to easily manage social media listening, engagement and publishing, while also building more comprehensive customer personas. The Falcon platform recently won a Facebook Innovation Spotlight award in the “Personalized Marketing to Scale” category and previously received the 2013 Bully Award for excellence in Innovation. “All institutions, not just higher education, can benefit from a centralized approach to social media,” added Aaron Ketry, Falcon.io’s North American sales director. “Our platform is ideally suited for organizations that are looking for a unified and scalable tool to better understand their different customer profiles while centralizing social media management, social listening and community management.” Falcon.io offers an integrated SaaS platform for social media listening, engaging, publishing and managing customer data. The company enables their clients to explore the full potential of digital marketing by managing multiple customer touchpoints from one platform. Falcon.io’s diverse and global client portfolio includes Carlsberg, Flying Tiger Copenhagen, Nintendo of Europe, IWC Watches, Mentos, Redken, Coca-Cola and many more. Columbia University is one of the world's most important centers of research and at the same time a distinctive and distinguished learning environment for undergraduates and graduate students in many scholarly and professional fields. The University recognizes the importance of its location in New York City and seeks to link its research and teaching to the vast resources of a great metropolis. It seeks to attract a diverse and international faculty and student body, to support research and teaching on global issues, and to create academic relationships with many countries and regions. It expects all areas of the university to advance knowledge and learning at the highest level and to convey the products of its efforts to the world.


News Article | February 16, 2017
Site: www.prweb.com

Strategic Communications announced today it has achieved Cisco® Gold Certification. To earn Gold Certification, Strategic Communications met rigorous standards set forth by Cisco in networking competency, service, support and customer satisfaction. “The Strategic Team has been working on this effort for the past two years, we are delighted we have met our goal in achieving Cisco Gold Certification”, says Kathy Mills – Owner and CEO of Strategic Communications. “This accomplishment required hard work, diligence and sacrifice from the entire Strategic Team. Strategic Communications is looking forward to building a stronger business relationship with the Cisco Team.” The Cisco® Channel Partner Program provides a framework for partners to build the sales, technical and Cisco Lifecycle Services skills required to deliver Cisco solutions to end customers. Through the program's specializations and certifications, Cisco recognizes a partner's expertise in deploying solutions based on Cisco advanced technologies and services. Using a third-party audit process, the program validates a partner’s technology skills, business practices, customer satisfaction, presales and post-sales support capabilities, and other critical factors that customers consider when choosing a trusted partner. As a Cisco Gold Certified Partner, Strategic Communications has met the requirements for attaining the broadest range of expertise across multiple technologies by achieving Cisco advanced specializations in the four following areas: enterprise networks architecture, security architecture, collaboration architecture and data center architecture. In addition, Strategic Communications has integrated Cisco Hybrid IT, the resale of cloud and managed services, into its offerings and is required to ensure high customer satisfaction in collaboration with Cisco. Cisco Gold Certification provides Strategic Communications with access to comprehensive sales, technical, and lifecycle services training and support available from Cisco. Strategic Communications is a Women Owned Small Business technology company based in Louisville, KY. Founded in 1994, Strategic’s Federal, Commercial, SLED and Engineering Team has provided an array of Networking, Collaboration, AV/VTC, Security and Cloud solutions to resolve their customer’s business challenges. Strategic’s customer base includes The United States DOD and Civilian Agencies, and many Fortune 500 companies. Strategic was awarded a multitude of government contracts including NASA SEWP V, NITAAC CIO-CS, SPAWAR, SEAPORT-E, SOCOM, Centcom, AFRL, MCNOSC, UHUHS, GITM, NAVALWARFARE, NASPO ValuePoint, and many others. Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at http://www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.


News Article | February 15, 2017
Site: www.marketwired.com

LAS VEGAS, NV--(Marketwired - Feb 8, 2017) - Her Imports ( : EZJRD), a leading retailer of human hair extensions and related beauty products, today announced that it has retained KCSA Strategic Communications, a leading New York-based communications firm, to lead the Company's strategic communications and investor relations programs. KCSA intends to deploy an investor relations campaign designed to increase awareness of Her Imports among the investment community through a comprehensive communications strategy. KCSA's objectives include, among others, communications, strategy and introductions to the institutional investment community. Since KCSA's inception nearly fifty years ago, the firm has developed a strong reputation for its work representing public companies. Barry Hall, Chief Executive Officer of Her Imports, stated, "We are eager to begin working with the entire KCSA team on strategic communications and investor relations. Management and the Board of Directors believe that now is the right time to engage a top tier communications firm to assist us in presenting our opportunity to the investment community. Her Imports is gaining more traction everyday with our products and services and we want to proactively communicate this story on a national scale." Todd Fromer, Managing Partner of KCSA Strategic Communications, commented, "With an extensive history of providing expert strategic communications and our established network of investors, we believe KCSA is the right firm to focus Her Imports' communication strategy and help tell this compelling story to key institutional investors. We are pleased to implement this communications plan based on best practices for Her Imports." About KCSA Strategic Communications: KCSA is a fully integrated communications agency specializing in public relations, investor relations and social media, with expertise in financial and professional services, technology, healthcare, digital media and energy. Since 1969, the firm has demonstrated strategic thinking and program execution that drives results for its clients in the ever-changing communications and digital landscape. The firm's clients are its best references. For more information, please visit www.kcsa.com. About Her Imports: Her Imports sells human hair extensions and related hair-care and beauty products at retail locations throughout the U.S. and on our Website, www.herimports.com. Additionally, by way of our proprietary eCommerce platform and strategic leveraging of social media buys, we convert prospects into customers while developing long-term personal relationships and loyal customers. Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of EZJR, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. EZJR, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by applicable securities laws. For more information, please refer to EZJR, Inc.'s financial statements as filed with the Securities and Exchange Commission.


News Article | February 28, 2017
Site: globenewswire.com

WASHINGTON, Feb. 28, 2017 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE:FCN) today released its financial results for the fourth quarter and full year ended December 31, 2016. Commenting on these results, Steven H. Gunby, President and Chief Executive Officer of FTI Consulting, said, “2016 was a superb year for FTI Consulting. We delivered record revenues in Economic Consulting and Corporate Finance & Restructuring, and had another year of strong performance in Strategic Communications. And our EMEA region is benefitting from our multi-year commitment to grow our global platform, delivering record revenues and continuing to grow headcount substantially.” For the full year 2016, revenues increased 1.8% to $1.81 billion compared to $1.78 billion in the prior year. Excluding the estimated negative impact of foreign currency translation (“FX”), revenues increased 3.6% compared to the prior year. The increase in revenues was driven by broad-based higher demand across the Economic Consulting segment and higher demand for restructuring services in the Corporate Finance & Restructuring segment. This strength was partially offset by reduced demand in the Technology and Forensic and Litigation Consulting segments. Net income increased 29.5% to $85.5 million compared to $66.1 million in the prior year. Adjusted EBITDA was $203.0 million, or 11.2% of revenues, compared to $205.8 million, or 11.6% of revenues, in the prior year. Adjusted EBITDA growth in the Economic Consulting, Corporate Finance & Restructuring and Strategic Communications segments was more than offset by Adjusted EBITDA declines in the Technology and Forensic and Litigation Consulting segments and higher corporate costs. The decline in Adjusted EBITDA and Adjusted EBITDA Margin was also impacted by higher costs primarily from higher compensation related to an increase in aggregate headcount, which was not sufficiently offset by higher revenues. Full year 2016 fully diluted earnings per share (“EPS”) were $2.05 compared to $1.58 in the prior year. Full year 2015 EPS included a $19.6 million debt extinguishment charge, which reduced EPS by $0.28. Full year 2016 EPS included: Full year 2016 Adjusted EPS were $2.24 compared to $1.84 in the prior year. Adjusted EPS in 2016 excludes the $10.4 million special charge related to headcount reductions and a $1.4 million fair value adjustment for an acquisition contingent consideration liability. Cash and cash equivalents were $216.2 million at December 31, 2016, compared to $149.8 million at December 31, 2015. In 2016, the Company spent $21.5 million to repurchase 537,400 shares of its common stock at an average price of $39.97. As of December 31, 2016, approximately $81.4 million remained available under the Company’s $100.0 million share repurchase authorization. The Company reduced the balance drawn on its credit facility by $130.0 million during 2016. Total debt of $370.0 million at December 31, 2016 compares to total debt of $500.0 million at December 31, 2015. Total debt, net of cash, was $153.8 million at December 31, 2016, down from $350.2 million at December 31, 2015. Fourth quarter 2016 revenues of $441.9 million compared to revenues of $442.2 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues increased 2.6% compared to the prior year quarter. Excluding FX, the increase in revenues was primarily driven by higher demand for mergers and acquisition (“M&A”) related antitrust services in the Economic Consulting segment, which was partially offset by lower demand in the dispute advisory and health solutions practices within the Forensic and Litigation Consulting segment. Net income of $7.1 million decreased 31.4% compared to $10.3 million in the prior year quarter. Adjusted EBITDA was $30.3 million, or 6.9% of revenues, compared to $35.2 million, or 8.0% of revenues in the prior year quarter. The decline in Adjusted EBITDA was due to higher compensation related to increased headcount in the Corporate Finance & Restructuring segment and lower demand in the Forensic and Litigation Consulting segment. Fourth quarter 2016 EPS were $0.17 compared to $0.25 in the prior year quarter. Fourth quarter 2016 EPS included a special charge of $3.6 million related to headcount reductions and a $3.8 million write-down of capitalized software. These charges were partially offset by a $3.7 million reduction in income tax expense. Fourth quarter 2016 Adjusted EPS of $0.24 were the same as the prior year quarter. Adjusted EPS excludes the impact of the $3.6 million special charge related to headcount reductions. Corporate Finance & Restructuring Revenues in the Corporate Finance & Restructuring segment increased $1.8 million, or 1.6%, to $113.4 million in the quarter compared to $111.6 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues increased $4.4 million, or 3.9%, compared to the prior year quarter. The increase in revenues were primarily due to higher realized pricing for restructuring services and higher success fees, which was partially offset by lower demand. Adjusted Segment EBITDA was $16.3 million, or 14.4% of segment revenues, compared to $18.9 million, or 17.0% of segment revenues, in the prior year quarter. The decline in Adjusted Segment EBITDA was due to higher compensation costs, which were partially offset by lower bad debt expense and increased revenues. Forensic and Litigation Consulting Revenues in the Forensic and Litigation Consulting segment decreased $11.2 million, or 9.6%, to $105.5 million in the quarter compared to $116.7 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues decreased $9.8 million, or 8.4%, compared to the prior year quarter. The decrease in revenues was primarily due to lower demand in the segment’s dispute advisory and health solutions practices. Adjusted Segment EBITDA was $6.3 million, or 6.0% of segment revenues, compared to $8.8 million, or 7.5% of segment revenues, in the prior year quarter. The decline in Adjusted Segment EBITDA was due to lower revenues, which were partially offset by lower compensation costs resulting from headcount reductions in the health solutions practice. Economic Consulting Revenues in the Economic Consulting segment increased $10.7 million, or 9.0%, to $129.3 million in the quarter compared to $118.6 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues increased $15.0 million, or 12.6%, compared to the prior year quarter. The increase in revenues was driven primarily by higher demand for M&A-related antitrust services. Adjusted Segment EBITDA was $19.0 million, or 14.7% of segment revenues, compared to $18.8 million, or 15.9% of segment revenues, in the prior year quarter. Adjusted Segment EBITDA was up only slightly from the prior year quarter as the increase in revenues was partially offset by higher compensation costs, primarily related to an increase in professionals and shifts in business mix. Technology Revenues in the Technology segment decreased $3.1 million, or 6.6%, to $43.5 million in the quarter compared to $46.6 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues decreased $2.3 million, or 4.8%, compared to the prior year quarter. The decrease in revenues was primarily due to lower demand and lower realized pricing for M&A-related “second request” and litigation services. Adjusted Segment EBITDA was $5.6 million, or 12.8% of segment revenues, compared to $6.0 million, or 12.8% of segment revenues, in the prior year quarter. The decline in Adjusted Segment EBITDA was due to lower revenues, which were partially offset by lower compensation costs resulting from headcount reductions taken in 2016. Strategic Communications Revenues in the Strategic Communications segment increased $1.6 million or 3.2%, to $50.3 million in the quarter compared to $48.8 million in the prior year quarter. Excluding the estimated negative impact of FX, revenues increased $4.3 million, or 8.8%, compared to the prior year quarter. The increase in revenues was primarily due to higher project-based revenues in the Europe, Middle East and Africa (“EMEA”) region, driven by public affairs and financial communications engagements. Adjusted Segment EBITDA was $8.4 million, or 16.7% of segment revenues, compared to $7.6 million, or 15.6% of segment revenues, in the prior year quarter. The increase in Adjusted Segment EBITDA was due to the increase in revenues, which were partially offset by higher compensation costs, primarily related to an increase in professionals. 2017 Guidance The Company estimates that revenues for 2017 will range between $1.80 billion and $1.90 billion. The Company estimates that EPS will range between $1.95 and $2.30 and that Adjusted EPS will range between $2.10 and $2.40. The variance between EPS and Adjusted EPS guidance for 2017 is related to estimated lease cancellation charges of $0.10 to $0.15 per share for the move of the Company’s Washington, D.C., office to another Washington, D.C., office location. The Company’s guidance assumes the completion of the remaining $81.4 million of its $100.0 million share repurchase authorization in 2017, which will be dependent on fluctuations in the price per share of the Company’s common stock, the timing of stock repurchases, market conditions and other future events that may be beyond the Company’s control. Fourth Quarter and Full Year 2016 Conference Call FTI Consulting will host a conference call for analysts and investors to discuss fourth quarter and full year 2016 financial results at 9:00 a.m. Eastern Time on February 28, 2017. The call can be accessed live and will be available for replay over the Internet for 90 days by logging onto the Company's investor relations website here. About FTI Consulting FTI Consulting, Inc. is a global business advisory firm dedicated to helping organizations manage change, mitigate risk and resolve disputes: financial, legal, operational, political & regulatory, reputational and transactional. With more than 4,700 employees located in 29 countries, FTI Consulting professionals work closely with clients to anticipate, illuminate and overcome complex business challenges and make the most of opportunities. The Company generated $1.81 billion in revenues during fiscal year 2016. More information can be found at www.fticonsulting.com. We have included the definitions of Segment Operating Income (Loss) and Adjusted Segment EBITDA below in order to more fully define the components of certain non-GAAP financial measures presented in this earnings release. We define Segment Operating Income (Loss) as a segment’s share of Consolidated Operating Income (Loss). We define Total Segment Operating Income (Loss), which is a non-GAAP financial measure, as the total of Segment Operating Income (Loss) for all segments, which excludes unallocated corporate expenses. We use Segment Operating Income (Loss) for the purpose of calculating Adjusted Segment EBITDA. We define Adjusted Segment EBITDA as a segment’s share of Consolidated Operating Income (Loss) before depreciation, amortization of intangible assets, remeasurement of acquisition-related contingent consideration, special charges and goodwill impairment charges. We use Adjusted Segment EBITDA as a basis to internally evaluate the financial performance of our segments because we believe it reflects current core operating performance and provides an indicator of the segment’s ability to generate cash. We define Adjusted Segment EBITDA Margin as Adjusted Segment EBITDA as a percentage of a segment’s revenues. We define Total Adjusted Segment EBITDA, which is a non-GAAP financial measure, as the total of Adjusted Segment EBITDA for all segments, which excludes unallocated corporate expenses. We define Adjusted EBITDA, which is a non-GAAP financial measure, as consolidated net income before income tax provision, other non-operating income (expense), depreciation, amortization of intangible assets, remeasurement of acquisition-related contingent consideration, special charges, goodwill impairment charges and losses on early extinguishment of debt. We believe that the non-GAAP financial measures, which exclude the effects of remeasurement of acquisition-related contingent consideration, special charges and goodwill impairment charges, when considered together with our GAAP financial results and GAAP measures, provide management and investors with a more complete understanding of our operating results, including underlying trends. In addition, EBITDA is a common alternative measure of operating performance used by many of our competitors. It is used by investors, financial analysts, rating agencies and others to value and compare the financial performance of companies in our industry. Therefore, we also believe that these measures, considered along with corresponding GAAP measures, provide management and investors with additional information for comparison of our operating results with the operating results of other companies. We define Adjusted Net Income and Adjusted Earnings per Diluted Share (“Adjusted EPS”), which are non-GAAP financial measures, as net income and earnings per diluted share, respectively, excluding the impact of remeasurement of acquisition-related contingent consideration, special charges, goodwill impairment charges and losses on early extinguishment of debt. We use Adjusted Net Income for the purpose of calculating Adjusted EPS. Management uses Adjusted EPS to assess total Company operating performance on a consistent basis. We believe that this non-GAAP financial measure, which excludes the effects of the remeasurement of acquisition-related contingent consideration, special charges, goodwill impairment charges and losses on early extinguishment of debt, when considered together with our GAAP financial results, provides management and investors with an additional understanding of our business operating results, including underlying trends. Non-GAAP financial measures are not defined in the same manner by all companies and may not be comparable with other similarly titled measures of other companies. Non-GAAP financial measures should be considered in addition to, but not as a substitute for or superior to, the information contained in our Condensed Consolidated Statements of Comprehensive Income. Reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures are included in the financial tables accompanying this press release. Safe Harbor Statement This press release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve uncertainties and risks. Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events, future revenues, future results and performance, expectations, plans or intentions relating to acquisitions, share repurchases and other matters, business trends and other information that is not historical, including statements regarding estimates of our future financial results. When used in this press release, words such as "estimates," "expects," "anticipates," "projects," "plans," "intends," "believes,” "forecasts" and variations of such words or similar expressions are intended to identify forward-looking statements. All forward-looking statements, including, without limitation, estimates of our future financial results, are based upon our expectations at the time we make them and various assumptions. Our expectations, beliefs and projections are expressed in good faith, and we believe there is a reasonable basis for them. However, there can be no assurance that management's expectations, beliefs and estimates will be achieved, and the Company's actual results may differ materially from our expectations, beliefs and estimates. Further, preliminary results are subject to normal year-end adjustments. The Company has experienced fluctuating revenues, operating income and cash flow in prior periods and expects that this will occur from time to time in the future. Other factors that could cause such differences include declines in demand for, or changes in, the mix of services and products that we offer, the mix of the geographic locations where our clients are located or where services are performed, adverse financial, real estate, fluctuations in the price per share of our common stock, other market and general economic conditions and other future events, which could impact each of our segments differently and could be outside of our control, the pace and timing of the consummation and integration of future acquisitions, the Company's ability to realize cost savings and efficiencies, competitive and general economic conditions, retention of staff and clients and other risks described under the heading "Item 1A Risk Factors" in the Company's most recent Form 10-K filed with the SEC and in the Company's other filings with the SEC, including the risks set forth under "Risks Related to Our Reportable Segments" and "Risks Related to Our Operations". We are under no duty to update any of the forward looking statements to conform such statements to actual results or events and do not intend to do so.


Grant
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: DRS-04-2014 | Award Amount: 1.38M | Year: 2015

The European Union (EU) faces a growing health security threat posed by pandemics due to the convergence of risk factors driving disease emergence, amplification and dissemination of pathogens with pandemic potential. Protecting the health and security of citizens in the EU in the face of these pandemic threats requires a coherent response by all stakeholders driven by effective pandemic risk management. PANDEM will contribute to the reduction in the health, socio-economic and security consequences of future pandemics so that society will be better prepared at regional, national, EU and global level. PANDEM will assess current pandemic preparedness and response tools, systems and practice at national, EU and global level in priority areas including risk assessment and surveillance, communication and public information, governance and legal frameworks. PANDEM will then identify gaps and improvement needs leading to the development of viable innovative concepts and analysis of the feasibility of a future demonstration project to strengthen capacity-building for pandemic risk management in the EU. PANDEM specifically addresses the needs and priorities detailed in the Horizon 2020 Work Programme crisis management topic DRS-4. PANDEM will focus on the needs and requirements of users and first responders across the spectrum of pandemic risk management. PANDEM will bring together highly skilled and multi-disciplinary senior experts from the health, security, defence, microbiology, communications, information technology and emergency management fields. Given the cross-border and multi-sectoral context of the health and security challenge for building pandemic risk management capacity, a systems-based methodology will be applied and the final outcome will be developed for use in a pan-European setting.

Loading Strategic Communications collaborators
Loading Strategic Communications collaborators